With occupancy nearing 90% across its existing facilities, Labshares is expanding to more than 100,000 square feet to meet demand for flexible, capital-efficient lab space that helps biotechs scale smarter and focus on science.

‍

Watertown, Mass. (November 13, 2025) — Labshares, Greater Boston’s leading shared-laboratory operator for biotechnology companies, today announced that it has signed a lease for a new 57,882-square-foot facility at 66 Galen Street in Watertown, more than doubling its footprint to over 100,000 square feet of turnkey lab and office space designed to grow with its member companies. The expansion strengthens Labshares’ ability to support more emerging biotech companies developing therapies, diagnostics, and medical devices within the world’s leading biotech hub.

‍

The newly leased space will open in two phases, with Phase 1 scheduled for Q2 2026 and Phase 2 for Q4 2026. Labshares will continue to operate its existing sites at 55 Chapel Street and 90 Bridge Street in Newton. Together, these locations expand the company’s presence within Greater Boston’s life sciences corridor.

‍

At a time when much of the biotech market is contracting, Labshares is expanding. It currently operates at nearly 90 percent occupancy, with a 77 percent renewal rate and an average member satisfaction score of 3.8 out of 4.0. Since 2022, more than 70 percent of Labshares members have expanded their footprint within Labshares, underscoring the strength of its capital-efficient model that helps biotech companies scale even in a cautious funding environment.

‍

Labshares’ shared-laboratory model provides fully equipped, ready-to-use lab and office space supported by on-site operational, compliance, and technical teams, allowing scientists to focus on research instead of facilities management. Members share access to more than $10 million in advanced lab instrumentation—including a cell sorter, spectral flow cytometers, and other cutting-edge equipment—all OEM-maintained and continually updated. This all-inclusive model reduces lab operating costs by 60 to 70 percent compared with traditional leases or subleases.

‍

Unlike traditional biotech incubators, which typically support companies only for their first 12 to 18 months, Labshares offers a continuum of space and services that allows companies to start, stay, and scale in one place. The average tenure of Labshares members is over three years and continues to rise, reflecting how modern biotech operates: lean teams, new discovery tools, and milestone-driven progress that demand flexibility and efficiency rather than massive lab buildouts.

‍

“This expansion reflects the continued demand for lab solutions that help biotech companies grow sustainably in all market cycles,” said Philip Borden, CEO of Labshares. “Biotech R&D has evolved. Smaller teams, faster discovery cycles, and new technologies like AI require a different approach. Labshares offers cost efficiency and flexibility in equal measure—enabling companies to advance discovery faster, operate more efficiently, and help define the future of biotech.”

‍

Founded in 2018, Labshares currently supports 25 companies ranging from seed-stage startups to publicly traded firms and has been home to more than 90 companies since its inception. Nearly 40 percent of current members are profitable or have raised over $100 million in funding.

‍

“As we advanced through preclinical discovery into a clinical company, Labshares gave us the flexibility to scale operations without the usual infrastructure hurdles,” said Dr. Kate Yen, Founder and CEO of Auron Therapeutics. “The capital efficiency of the model, combined with access to top-tier equipment and a supportive team, allowed us to stay focused on science instead of facilities and divert capital toward our lead program, which has now entered Phase 1 development. In many ways, we’ve grown up at Labshares—it’s been the ideal place to do that.”

‍

The new Watertown facility also reinforces the city’s growing position as a hub for life sciences innovation. Located minutes from Labshares’ Newton site, 66 Galen Street, owned by The Davis Companies, offers state-of-the-art lab infrastructure, free underground parking, and multiple public transit and shuttle options, providing a convenient, cost-effective alternative to Kendall Square and the Seaport. Labshares’ new building will be 95 percent leased, supporting a vibrant community of life sciences companies in the emerging hub of Watertown.

With this expansion, Labshares continues to build on its mission to create a smarter, more sustainable future for biotech—one that helps companies scale science efficiently while remaining rooted in Greater Boston’s innovation ecosystem. Learn more at www.labshares.com.

‍

About Labshares

Labshares is Greater Boston’s leading shared-laboratory platform for emerging and growing biotechnology companies. Founded in 2018, Labshares provides fully equipped, turnkey lab and office space that enables companies to scale efficiently. With flexible membership options, in-house technical support, and access to more $10 million in advanced lab instrumentation, Labshares offers a long-term,capital-efficient alternative to traditional lab leases and short-term biotech incubators. The company currently operates in Newton, Mass., and will expand to more than 100,000 square feet in 2026. www.labshares.com.

‍